| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20002274 | HPV | ENSG00000215644.10 | protein_coding | GCGR | No | No | 2642 | P47871 |
| TVIS20020716 | HPV | ENSG00000215644.10 | protein_coding | GCGR | No | No | 2642 | P47871 |
| TVIS20020717 | HPV | ENSG00000215644.10 | protein_coding | GCGR | No | No | 2642 | P47871 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GCGR |
|---|---|
| DrugBank ID | DB15226 |
| Drug Name | Dasiglucagon |
| Target ID | BE0000527 |
| UniProt ID | P47871 |
| Regulation Type | agonist |
| PubMed IDs | 33934456 |
| Citations | Battelino T, Tehranchi R, Bailey T, Dovc K, Melgaard A, Yager Stone J, Woerner S, von dem Berge T, DiMeglio L, Danne T: Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021 Aug;22(5):734-741. doi: 10.1111/pedi.13220. Epub 2021 Jun 9. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
